Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2023-05-09 Regulatory Filings
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
bioMérieux obtient la dérogation CLIA* de la Food and Drug Administration (FDA) américaine pour le test respiratoire BIOFIRE® SPOTFIRE® (R) Panel Mini
Regulatory Filings Classification · 100% confidence The document is a press release dated May 9, 2023, announcing that bioMérieux received a CLIA waiver from the US FDA for its BIOFIRE® SPOTFIRE® (R) Panel Mini respiratory test. It details the product, its capabilities (detecting 5 viruses in 15 minutes), and the implications of the FDA approval. This type of announcement, focusing on a specific regulatory milestone or product update, is typically classified as an Earnings Release (ER) if it were quarterly results, or more generally, a Regulatory Filing (RNS) or a general press release. However, given the content is a specific, positive regulatory achievement announcement rather than a comprehensive financial report (10-K, IR) or a management discussion (MDA), and it is not a transcript (CT) or a formal shareholder communication (DEF 14A, PSI), the most fitting category among the provided options for a significant, non-financial-results-focused announcement is often the general Regulatory Filings (RNS) or, if it were a brief update on a specific event, potentially a Legal/Regulatory update (LTR). Since this is a positive announcement about regulatory clearance/waiver, it functions as a general corporate update. Given the options, and since it is not a formal financial report, a management discussion, or a specific legal proceeding, RNS (Regulatory Filings - general regulatory announcements) is the most appropriate fallback, although it is a very specific type of announcement. It is not an ER because it is not focused on financial results. It is not LTR as it is a positive regulatory achievement, not a lawsuit. Therefore, RNS is the best fit as a general regulatory announcement/press release.
2023-05-09 French
bioMérieux – First-Quarter 2023 Business Review
Interim / Quarterly Report Classification · 95% confidence The document is a 'First-Quarter 2023 Business Review' from bioMérieux. It provides detailed quarterly sales figures, analysis by application and region, and operational highlights. It contains substantive financial data for the three-month period ended March 31, 2023, which qualifies it as an interim/quarterly report rather than just an earnings release or a simple announcement. It is not a full 10-K or annual report, but a comprehensive quarterly financial update. Q1 2023
2023-04-27 English
bioMérieux – Information financière du 1er trimestre 2023
Earnings Release Classification · 100% confidence The document is titled "bioMérieux – Information financière du 1er trimestre 2023" (bioMérieux – First Quarter 2023 Financial Information). It provides detailed financial figures (revenue, growth rates, regional breakdowns) for the first quarter ending March 31, 2023. It includes key performance indicators, management commentary, and a financial calendar. This structure is characteristic of a comprehensive report covering a period shorter than a full year, which aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report (RPA) because it contains the full substance of the quarterly results, nor is it the Annual Report (10-K). Q1 2023
2023-04-27 French
Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement to develop innovative infectious disease diagnostics
Regulatory Filings Classification · 95% confidence The document is explicitly titled "*PRESS RELEASE*" and announces a strategic partnership agreement between Oxford Nanopore and bioMérieux regarding infectious disease diagnostics. It contains quotes from CEOs, background information on both companies, and contact details for media/investor relations. This format is characteristic of a general corporate announcement or news release, which does not fit the specific definitions for financial reports (10-K, IR, ER), shareholder actions (DIV, DVA), or management changes (MANG). Since it is a general, non-regulatory announcement that doesn't fit the highly specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate fallback category is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory or corporate announcements not covered elsewhere.
2023-04-14 English
Oxford Nanopore et bioMérieux signent un partenariat stratégique pour développer des solutions innovantes dans le diagnostic des maladies infectieuses
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a strategic partnership between Oxford Nanopore and bioMérieux regarding infectious disease diagnostics. It details the nature of the collaboration, includes quotes from CEOs, provides 'About Us' sections for both companies, and lists contact information. This format is characteristic of a general corporate announcement or news release, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific capital action. Since it is a general announcement that doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate classification is the general regulatory/corporate announcement fallback category, RNS (Regulatory Filings), as it serves as a public disclosure of a significant business event.
2023-04-14 French
bioMérieux receives US FDA 510(k) clearance for the BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini and will apply for CLIA-waiver
Regulatory Filings Classification · 95% confidence The document is a press release from bioMérieux announcing that they received US FDA 510(k) clearance for a new diagnostic panel and that they will immediately apply for CLIA-waiver. It details the product, its benefits, and includes quotes from executives. This type of announcement, focusing on a specific operational or regulatory achievement (FDA clearance) and providing context, is characteristic of a general regulatory announcement or press release that doesn't fit the specific financial report categories (like 10-K, ER, IR). Since it is a specific, non-financial regulatory/operational update, and it is not a standard financial filing, the most appropriate general category is Regulatory Filings (RNS), as it serves as a general regulatory announcement. It is not an Earnings Release (ER) as it focuses on product clearance, not financial results. It is not an Investor Presentation (IP) or Call Transcript (CT). It is a formal announcement, but not one of the highly specific ones listed (like DIRS, DIV, CAP, etc.). Therefore, RNS is the best fit.
2023-04-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.